156 related articles for article (PubMed ID: 36879786)
1. Efficacy and safety of KL-A167 in previously treated recurrent or metastatic nasopharyngeal carcinoma: a multicenter, single-arm, phase 2 study.
Shi Y; Qin X; Peng X; Zeng A; Li J; Chen C; Qiu S; Pan S; Zheng Y; Cai J; Chen X; Qu S; Lin L; Huang J; Wu H; Lu Y; Wang W; Hu C; He X; Yu Z; Liu X; Xie B; Liu A; Hu G; Jing S; Zhang Q; Guo R; Li Q; Hong J; Jin F; Meng J; Shi J; Wang P; Cui J; Yang K; Zhang X; Li X; Shen L; He Y; Zhai L; Sun X; Ge J; Qing Y; Zong D
Lancet Reg Health West Pac; 2023 Feb; 31():100617. PubMed ID: 36879786
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of cadonilimab in previously treated recurrent or metastatic nasopharyngeal carcinoma(COMPASSION-06): A phase II multicenter study.
Chen QY; Guo SS; Luo Y; Qu S; Wu DH; Chen XZ; Chen DP; Qin XT; Lin Q; Jin F; Lin SJ; Yao ZF; Liu W; Maxwell Wang Z; Li BY; Xia M; Xu RH; Tang LQ; Mai HQ
Oral Oncol; 2024 Apr; 151():106723. PubMed ID: 38387261
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Limertinib (ASK120067) in Patients With Locally Advanced or Metastatic EGFR Thr790Met-Mutated NSCLC: A Multicenter, Single-Arm, Phase 2b Study.
Shi Y; Li B; Wu L; Pan Y; Pan Z; Liu Y; Fan Y; Ji Y; Fang J; Shi Q; Shi J; Gao H; Hu Y; Wang X; He Z; Ma R; Zhang Y; Jiang D; Bai Y; Zhang Y; Huang L; Zhou T; Liu H; Wang D; Wen Q; Chen G; Zang A; Wang X; Zhang X; Hu J; Yang R; Zhang G; Gu K; Wang L; Wang Q; Wei Z; Li Z; Lu H; Zhang H; Chen H; Song T
J Thorac Oncol; 2022 Oct; 17(10):1205-1215. PubMed ID: 35659581
[TBL] [Abstract][Full Text] [Related]
4. Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02).
Wang FH; Wei XL; Feng J; Li Q; Xu N; Hu XC; Liao W; Jiang Y; Lin XY; Zhang QY; Yuan XL; Huang HX; Chen Y; Dai GH; Shi JH; Shen L; Yang SJ; Shu YQ; Liu YP; Wang W; Wu H; Feng H; Yao S; Xu RH
J Clin Oncol; 2021 Mar; 39(7):704-712. PubMed ID: 33492986
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of Pucotenlimab (HX008) - a humanized immunoglobulin G4 monoclonal antibody in patients with locally advanced or metastatic melanoma: a single-arm, multicenter, phase II study.
Cui C; Chen Y; Luo Z; Zou Z; Jiang Y; Pan H; Fan Q; Zhao J; Xu Q; Jiang R; Wang X; Ma T; Guo Z; Si L; Chi Z; Sheng X; Dou Y; Tan Q; Wu D; Guo J
BMC Cancer; 2023 Feb; 23(1):121. PubMed ID: 36747118
[TBL] [Abstract][Full Text] [Related]
6. Efficacy, safety, and biomarker analysis of Camrelizumab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma (CAPTAIN study).
Yang Y; Zhou T; Chen X; Li J; Pan J; He X; Lin L; Shi YR; Feng W; Xiong J; Yang K; Yu Q; Zhang Q; Hu D; Sun Y; Hu G; Li P; Shen L; Lin Q; Zhang B; Qu X; Zou J; Zhang L; Fang W; Zhao Y
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34933967
[TBL] [Abstract][Full Text] [Related]
7. Efficacy, safety, and correlative biomarkers of bintrafusp alfa in recurrent or metastatic nasopharyngeal cancer patients: a phase II clinical trial.
Chiang CL; Lam TC; Li JCB; Chan KSK; El Helali A; Lee YYP; Law LHT; Zheng D; Lo AWI; Kam NW; Li WS; Cheung AKW; Chow JCH; Chan SPC; Lai JWY; Lee SWM; Kong FS; Ng WT; Kwong DLW; Lee AWM
Lancet Reg Health West Pac; 2023 Nov; 40():100898. PubMed ID: 37701718
[TBL] [Abstract][Full Text] [Related]
8. A Phase II Study of Nivolumab plus Gemcitabine in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma (KCSG HN17-11).
Jung HA; Park KU; Cho S; Lim J; Lee KW; Hong MH; Yun T; An HJ; Park WY; Pereira S; Ock CY; Keam B
Clin Cancer Res; 2022 Oct; 28(19):4240-4247. PubMed ID: 35819451
[TBL] [Abstract][Full Text] [Related]
9. Camrelizumab plus famitinib in patients with recurrent or metastatic nasopharyngeal carcinoma treated with PD-1 blockade: data from a multicohort phase 2 study.
Ding X; Hua YJ; Zou X; Chen XZ; Zhang XM; Xu B; Ouyang YF; Tu ZW; Li HF; Duan CY; Zhang WJ; You R; Liu YP; Liu YL; Yang Q; Huang PY; Wang SN; Fan J; Chen MY
EClinicalMedicine; 2023 Jul; 61():102043. PubMed ID: 37415845
[TBL] [Abstract][Full Text] [Related]
10. Association of Plasma Epstein-Barr Virus DNA With Outcomes for Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma Receiving Anti-Programmed Cell Death 1 Immunotherapy.
Xu JY; Wei XL; Ren C; Zhang Y; Hu YF; Li JY; Chen JL; Wang YQ; Han F; Wang FH
JAMA Netw Open; 2022 Mar; 5(3):e220587. PubMed ID: 35230439
[TBL] [Abstract][Full Text] [Related]
11. Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial.
Wang J; Lu S; Yu X; Hu Y; Sun Y; Wang Z; Zhao J; Yu Y; Hu C; Yang K; Feng G; Ying K; Zhuang W; Zhou J; Wu J; Leaw SJ; Zhang J; Lin X; Liang L; Yang N
JAMA Oncol; 2021 May; 7(5):709-717. PubMed ID: 33792623
[TBL] [Abstract][Full Text] [Related]
12. Metronomic oral cyclosphosphamide as third-line systemic treatment or beyond in patients with inoperable locoregionally advanced recurrent or metastatic nasopharyngeal carcinoma.
Lee VHF; Kwong DLW; Lam KO; Lai YC; Li Y; Tong CC; Ho PPY; Chan WL; Wong LS; Leung DKC; Chan SY; Chan FT; Leung TW; Lee AWM
Medicine (Baltimore); 2017 Apr; 96(15):e6518. PubMed ID: 28403082
[TBL] [Abstract][Full Text] [Related]
13. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials.
Fang W; Yang Y; Ma Y; Hong S; Lin L; He X; Xiong J; Li P; Zhao H; Huang Y; Zhang Y; Chen L; Zhou N; Zhao Y; Hou X; Yang Q; Zhang L
Lancet Oncol; 2018 Oct; 19(10):1338-1350. PubMed ID: 30213452
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of geptanolimab (GB226) for relapsed/refractory primary mediastinal large B-cell lymphoma: an open-label phase II study (Gxplore-003).
Shi Y; Cui J; Zhou H; Zhang X; Zou L; Cao J; Gao Y; Jin C; Li X; Liu H; Peng Z; Xie L; Zhang H; Zhang W; Zhang H; Zhong L; Zhou F; Guo G; He W
Cancer Immunol Immunother; 2023 Sep; 72(9):2991-3002. PubMed ID: 37289256
[TBL] [Abstract][Full Text] [Related]
15. Apatinib for the treatment of metastatic or locoregionally recurrent nasopharyngeal carcinoma after failure of chemotherapy: A multicenter, single-arm, prospective phase 2 study.
Ruan X; Liang JH; Pan Y; Cai R; Zhang RJ; He Z; Yang X; Niu Z; Jiang W
Cancer; 2021 Sep; 127(17):3163-3171. PubMed ID: 34043812
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab versus placebo in combination with paclitaxel and carboplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase II trial.
Zhou T; Yang Y; Ma S; Lin L; Zhou T; Zhang C; Ding X; Wang R; Feng G; Chen Y; Xu R; Huang Y; Zhang L
ESMO Open; 2021 Dec; 6(6):100313. PubMed ID: 34837744
[TBL] [Abstract][Full Text] [Related]
17. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
Ren Z; Xu J; Bai Y; Xu A; Cang S; Du C; Li Q; Lu Y; Chen Y; Guo Y; Chen Z; Liu B; Jia W; Wu J; Wang J; Shao G; Zhang B; Shan Y; Meng Z; Wu J; Gu S; Yang W; Liu C; Shi X; Gao Z; Yin T; Cui J; Huang M; Xing B; Mao Y; Teng G; Qin Y; Wang J; Xia F; Yin G; Yang Y; Chen M; Wang Y; Zhou H; Fan J;
Lancet Oncol; 2021 Jul; 22(7):977-990. PubMed ID: 34143971
[TBL] [Abstract][Full Text] [Related]
18. Avelumab for platinum-ineligible/refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck: phase Ib results from the JAVELIN Solid Tumor trial.
Guigay J; Lee KW; Patel MR; Daste A; Wong DJ; Goel S; Gordon MS; Gutierrez M; Balmanoukian A; Le Tourneau C; Mita A; Vansteene D; Keilholz U; Schöffski P; Grote HJ; Zhou D; Bajars M; Penel N
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34663640
[TBL] [Abstract][Full Text] [Related]
19. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial.
Patel MR; Ellerton J; Infante JR; Agrawal M; Gordon M; Aljumaily R; Britten CD; Dirix L; Lee KW; Taylor M; Schöffski P; Wang D; Ravaud A; Gelb AB; Xiong J; Rosen G; Gulley JL; Apolo AB
Lancet Oncol; 2018 Jan; 19(1):51-64. PubMed ID: 29217288
[TBL] [Abstract][Full Text] [Related]
20. Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma.
Sheng X; Yan X; Wang L; Shi Y; Yao X; Luo H; Shi B; Liu J; He Z; Yu G; Ying J; Han W; Hu C; Ling Y; Chi Z; Cui C; Si L; Fang J; Zhou A; Guo J
Clin Cancer Res; 2021 Jan; 27(1):43-51. PubMed ID: 33109737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
